COST-EFFECTIVENESS OF EXENATIDE VERSUS INSULIN GLARGINE AND VERSUS BIPHASIC INSULIN ASPART FOR THE TREATMENT OF TYPE 2 DIABETES IN PORTUGAL: A LONG-TERM HEALTH ECONOMIC ANALYSIS

被引：2
|
作者：
Palmer, J. L. [1 ]
Pinto, C. G. [2 ]
Duarte, R. [3 ]
Miguel, L. [4 ]
Gregor, Z. [5 ]
机构：
[1] IMS Hlth, Basel, Switzerland
[2] Inst Super Econ & Gestao, Lisbon, Portugal
[3] Portuguese Diabet Assoc, Lisbon, Portugal
[4] Univ Tecn Lisboa, CISEP, ISEG, Lisbon, Portugal
[5] Eli Lilly & Co, Prague, Czech Republic
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(11)72109-X
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A293 / A293
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF EXENATIDE VERSUS INSULIN GLARGINE FOR THE TREATMENT OF TYPE-2 DIABETES IN TURKEY: A LONG-TERM HEALTH ECONOMIC ANALYSIS
    Bruhn, D.
    Malhan, S.
    Kavuncubasi, S.
    Smith-Palmer, J.
    Reed, V
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A406 - A406
  • [2] COST-EFFECTIVENESS ANALYSIS OF BIPHASIC INSULIN ASPART VERSUS INSULIN GLARGINE IN PEOPLE WITH TYPE 2 DIABETES IN CHINA
    Xu, Z.
    Han, P.
    Wei, Y.
    Zhang, Y.
    Wu, J.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A247 - A247
  • [3] Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China
    James L. Palmer
    Amélie Beaudet
    Jeremy White
    Juliette Plun-Favreau
    Jayne Smith-Palmer
    [J]. Advances in Therapy, 2010, 27 : 814 - 827
  • [4] Cost-Effectiveness of Biphasic Insulin Aspart versus Insulin Glargine in Patients with Type 2 Diabetes in China
    Palmer, James L.
    Beaudet, Amelie
    White, Jeremy
    Plun-Favreau, Juliette
    Smith-Palmer, Jayne
    [J]. ADVANCES IN THERAPY, 2010, 27 (11) : 814 - 827
  • [5] Cost-effectiveness of exenatide versus insulin glargine for the treatinent of type 2 diabetes in a UK setting: a long-term health economic study
    Ray, J. A.
    Secnik, K.
    Yurgin, N.
    Valentine, W. J.
    Roze, S.
    McKendrick, J.
    Foos, V.
    Palmer, A. J.
    [J]. DIABETOLOGIA, 2006, 49 : 477 - 477
  • [6] Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting
    Valentine, WJ
    Palmer, AJ
    Lammert, M
    Nicklasson, L
    Foos, V
    Roze, S
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (12) : 2063 - 2071
  • [7] COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC/INSULIN ASPART VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES IN CHINA
    Liu, C.
    Tao, L. B.
    Wang, F.
    [J]. VALUE IN HEALTH, 2020, 23 : S111 - S111
  • [8] Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes
    Luo, Qiong
    Zhou, Li
    Zhou, Naitong
    Hu, Ming
    [J]. FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [9] COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC/INSULIN ASPART VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES IN CHINA
    Xu, J.
    Lan, K.
    Wang, J.
    [J]. VALUE IN HEALTH, 2020, 23 : S111 - S111
  • [10] COST-EFFECTIVENESS OF INSULIN DEGLUDEC/ASPART VERSUS BIPHASIC INSULIN ASPART IN PATIENTS WITH TYPE 2 DIABETES IN IRAN
    Saiyarsarai, P.
    Khosroshahi, Ghazizadeh A.
    Khedmati, J.
    Ghaffari, S.
    Soleymani, F.
    Seyyedifar, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S576 - S576
12345